• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

12-gene Recurrence Score can inform adjuvant therapy of colon cancer

byAndrew Bishara
November 16, 2013
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD  Oxaliplatin

1. The 12-gene Recurrence Score can predict recurrence risk and disease-free survival in both stage II and III colon cancer.

2. Higher scores may help predict absolute benefit of oxaliplatin for stage II and IIIA/B disease.

Evidence rating level:  2 (Good)

Study Rundown: Given the complex treatment options available for patients diagnosed with stage II or III colon cancer, accurate assessments of risk for recurrence may help to inform the management decisions of these patients. The 12-gene Recurrence Score assay has been previously validated in patients with stage II colon cancer. Therefore, the purpose of this study was to retrospectively determine the efficacy of this assay in patients with stage II and III colon cancer.

At the conclusion of the study, the authors determined that Recurrence Score predicted recurrence risk, as well as disease-free and overall survival in stage II and III colon cancer. Furthermore, they also concluded that the absolute benefit of oxaliplatin increased with higher scores, particularly in patients with stage II and IIIA/B disease. On the basis of these findings, the authors recommended that this assay be included in the clinical management of these patients in order to better inform adjuvant therapy decision-making. These conclusions are strengthened by the large sample sizes used in this study. However, it should be noted that the use of specimens from patients enrolled in previous clinical trials (National Surgical Adjuvant Breast and Bowel Project C-07) may limit the generalizability of these findings.

Click to read the article in JCO

RELATED REPORTS

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

United States-based chemotherapy regimen for Ewing sarcoma is more effective and safer than the standard European regimen

Inappropriate clinical management decisions are possible secondary to use of Bazett formula for QTc in context of chemotherapy cancer treatment

Relevant reading: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin

In-Depth [retrospective cohort study]: This clinical validation study of the 12-gene Recurrence Score assay was a prospectively designed review with pre-specified end points and analysis plan of archival tumor specimens. The specimens came from patients with stage II and III colon cancer randomly assigned to either fluorouracil (FU) or FU plus oxaliplatin in the National Surgical Adjuvant Breast and Bowel project. A total of 892 tumor specimens were examined and Recurrence Score calculated.

The study authors found that the Recurrence Score predicted recurrence (P < 0.001) as well as disease-free and overall survival ((P < 0.001). Its association with recurrence risk remained after adjustment for stage, mismatch repair, lymph nodes examined, grade and treatment. The relative benefit of oxaliplatin in addition to FU adjuvant therapy was similar across the range of Recurrence scores (P = 0.48); therefore, the authors concluded that the absolute benefit of oxaliplatin increased with higher scores, particularly in patients with stage II and IIIA/B disease.

By Monica Parks and Andrew Bishara

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

 

Tags: adjuvant therapychemotherapycolon canceroxaliplatinrecurrence riskstage II and IIIA/B cancer
Previous Post

Text messaging program for diabetes shows improved medication adherence

Next Post

Multiple births associated with increased healthcare costs

RelatedReports

No benefit of erlotinib in combined hepatocellular carcinoma treatment
Oncology

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

January 11, 2023
Increased frailty associated with childhood cancer survivorship
Chronic Disease

United States-based chemotherapy regimen for Ewing sarcoma is more effective and safer than the standard European regimen

November 9, 2022
Propofol appears safe and effective in procedural sedation for cardioversion
Oncology

Inappropriate clinical management decisions are possible secondary to use of Bazett formula for QTc in context of chemotherapy cancer treatment

October 3, 2022
#VisualAbstract: Induction chemotherapy with cisplatin plus  gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma
StudyGraphics

#VisualAbstract: Induction chemotherapy with cisplatin plus gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma

September 20, 2022
Next Post
Obtaining consent for c-section during labor may be suboptimal

Multiple births associated with increased healthcare costs

IUD contraception equally safe in teenagers as in older women

Lower-dose levonorgestrel IUD effective, well-tolerated

Early retroviral therapy reduces HIV-1 transmission [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options